Table 1.
Characteristics of patients at baseline.
| Characteristic | Values |
|---|---|
| Number of patients | 10 |
| Age, years | 64 ± 9 |
| Sex | |
| Female | 7 (70.0%) |
| Male | 3 (30.0%) |
| Distribution of emphysema | |
| Homogeneous | 8 (80.0%) |
| Heterogeneous | 2 (20.0%) |
| Treatment for lung disease | |
| β2-agonist | 10 (100.0%) |
| Anticholinergic | 10 (100.0%) |
| Inhaled corticosteroid | 8 (80.0%) |
| Systemic corticosteroid | 1 (10.0%) |
| Theophylline | 4 (40.0%) |
| Roflumilast | 2 (20.0%) |
| Acetylcysteine | 2 (20.0%) |
| Long-term oxygen therapy | 10 (100.0%) |
| Intermittent noninvasive ventilation | 7 (70.0%) |
| Blood gas analysis | |
| PaCO2 (mmHg) | 53 ± 5 |
| Base excess (mmol/l) | 7.2 ± 2.7 |
| HCO3- (mmol/l) | 32.9 ± 2.8 |
| pH | 7.42 ± 0.04 |
| Pulmonary function | |
| FEV1/FVC (%) | 32 ± 5 |
| FEV1 (l) | 0.5 ± 0.1 |
| FEV1 (% of predicted) | 17 ± 5 |
| FVC (l) | 1.5 ± 0.5 |
| FVC (% of predicted) | 42 ± 10 |
| TLC (l) | 7.6 ± 1.1 |
| TLC (% of predicted) | 130 ± 14 |
| RV (l) | 6.1 ± 0.9 |
| RV (% of predicted) | 280 ± 48 |
| RV/TLC (%) | 81 ± 5 |
| Rawtot (kPa•s/l) | 1.8 ± 0.6 |
| sRawtot (kPa•s) | 11.6 ± 4.6 |
| TLCO (ml/min/kPa) | 0.7 ± 0.3 |
| TLCO (% of predicted) | 8.6 ± 3.6 |
| 6-min walk test (m) | 203 ± 97 |
Values are given as mean and standard deviation or as absolute numbers and percentages.
FEV1, forced expired volume in one second; FVC, forced vital capacity; PaCO2, partial pressure of carbon dioxide in arterial blood; Rawtot, total airway resistance; RV, residual volume; sRawtot, specific total airway resistance; TLC, total lung capacity; TLCO, transfer factor of the lung for carbon monoxide.